JP2011512414A - 疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体 - Google Patents

疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体 Download PDF

Info

Publication number
JP2011512414A
JP2011512414A JP2010547737A JP2010547737A JP2011512414A JP 2011512414 A JP2011512414 A JP 2011512414A JP 2010547737 A JP2010547737 A JP 2010547737A JP 2010547737 A JP2010547737 A JP 2010547737A JP 2011512414 A JP2011512414 A JP 2011512414A
Authority
JP
Japan
Prior art keywords
pain
beloxepin
veloxepin
beroxepin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010547737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011512414A5 (de
Inventor
ブールドネク， ベルトランド ル
ローランド ドール，
Original Assignee
アドロー コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドロー コーポレイション filed Critical アドロー コーポレイション
Publication of JP2011512414A publication Critical patent/JP2011512414A/ja
Publication of JP2011512414A5 publication Critical patent/JP2011512414A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010547737A 2008-02-19 2009-02-19 疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体 Withdrawn JP2011512414A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2991308P 2008-02-19 2008-02-19
US2991608P 2008-02-19 2008-02-19
US2991508P 2008-02-19 2008-02-19
US5092108P 2008-05-06 2008-05-06
PCT/US2009/034461 WO2009105507A2 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2011512414A true JP2011512414A (ja) 2011-04-21
JP2011512414A5 JP2011512414A5 (de) 2012-04-05

Family

ID=40986169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010547737A Withdrawn JP2011512414A (ja) 2008-02-19 2009-02-19 疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体

Country Status (11)

Country Link
EP (1) EP2285818A4 (de)
JP (1) JP2011512414A (de)
KR (1) KR20100137473A (de)
CN (1) CN102007139A (de)
AU (1) AU2009215541A1 (de)
BR (1) BRPI0908098A2 (de)
CA (1) CA2715192A1 (de)
IL (1) IL207668A0 (de)
MX (1) MX2010009110A (de)
NZ (2) NZ594937A (de)
WO (1) WO2009105507A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
CN113546174A (zh) 2015-02-25 2021-10-26 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62754B1 (en) * 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
OA12969A (en) * 2002-12-11 2006-10-13 Pharmacia & Upjohn Co Llc Combination for the treatment of ADHD.
BRPI0415683A (pt) * 2003-11-03 2006-12-19 Warner Lambert Co inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
EP1828156A2 (de) * 2004-12-13 2007-09-05 Arena Pharmaceuticals, Inc. N-biaryl- und n-arylheteroarylpiperazinderivate als modulatoren des 5ht2c-rezeptors, die sich für die behandlung von damit in zusammenhang stehenden erkrankungen eignen
CN101107254B (zh) * 2005-01-27 2010-12-08 詹森药业有限公司 在中枢神经系统病症的治疗中作为5ht2抑制剂的杂环四环四氢呋喃衍生物
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EP1934193A1 (de) * 2005-09-29 2008-06-25 Wyeth a Corporation of the State of Delaware Benzothiadiazolyphenylalkylamin-derivate für die behandlung von mittels monoamin-wiederaufnahme verbesserten leiden
EP2015765A4 (de) * 2006-03-28 2011-11-23 Neopro Labs Llc Verfahren und zusammensetzungen zur behandlung von erkrankungen
GB0608655D0 (en) * 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
US20070281924A1 (en) * 2006-05-31 2007-12-06 Gaeta Federico C MIF inhibitors for treating neuropathic pain and associated syndromes

Also Published As

Publication number Publication date
BRPI0908098A2 (pt) 2015-08-18
NZ587896A (en) 2011-09-30
AU2009215541A1 (en) 2009-08-27
WO2009105507A3 (en) 2010-01-14
KR20100137473A (ko) 2010-12-30
NZ594937A (en) 2013-03-28
MX2010009110A (es) 2010-11-30
EP2285818A4 (de) 2011-08-17
EP2285818A2 (de) 2011-02-23
CN102007139A (zh) 2011-04-06
CA2715192A1 (en) 2009-08-27
WO2009105507A2 (en) 2009-08-27
IL207668A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
TWI422369B (zh) κ選擇性類鴉片受體拮抗劑
TWI224102B (en) Serotonergic agents
WO2015066344A1 (en) 5-ht2c receptor agonists and compositions and methods of use
JP2019512528A (ja) 抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
JP6929857B2 (ja) ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
EP3328835B1 (de) 5-ht2c-rezeptor-agonisten und zusammensetzungen und verfahren zur verwendung
JP2011512414A (ja) 疼痛を処置するための、ベロキセピン、その鏡像異性体および類似体
US20120178815A1 (en) Compositions of (-)-E-10-OH-NT and Methods for Their Synthesis and Use
JP2011512414A5 (de)
JP2018506514A (ja) 化合物、組成物および方法
US20090233958A1 (en) (+)-beloxepin and methods for its synthesis and use
TW200534848A (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders
US20090233957A1 (en) (-)-beloxepin and methods for its synthesis and use
WO2005000305A1 (en) 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
WO2006095187A1 (en) Benzoxazocines and their therapeutic use
Le Bourdonnec et al. BELOXEPIN AND METHODS FOR ITS SYNTHESIS AND USE
MX2008015434A (es) Combinanciones de inhibidores de recaptacion de monoamina y activadores de canales de potasio.
Kristensen et al. 5-HT2A Agonists for Use in Treatment of Depression
US7829576B2 (en) Beloxepin and analogs for the treatment of pain

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120216

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130619

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20130702